4-Benzimidazolyl-3-Phenylbutanoic Acids As Novel Pif-Pocket-Targeting Allosteric Inhibitors of Protein Kinase PKCζ
Citations Over TimeTop 11% of 2011 papers
Abstract
Protein kinase inhibitors with an allosteric mode of action are expected to reach, in many cases, higher selectivity for the target enzyme than ATP-competitive compounds. Therefore, basic research is aiming at identifying and establishing novel sites on the catalytic domain of protein kinases which might be targeted by allosteric inhibitors. We previously published the first structure-activity relationships (SARs) for allosteric activators of protein kinase PDK1. Here, we present the design, synthesis, and SAR data on a series of novel compounds, 4-benzimidazolyl-3-phenylbutanoic acids, that inhibit the atypical protein kinace C (PKC) ζ via binding to the PIF-pocket. Key positions were identified in the compounds that can be modified to increase potency and selectivity. Some congeners showed a high selectivity toward PKCζ, lacking inhibition of the most closely related isoform, PKCι, and of further AGC kinases. Furthermore, evidence is provided that these compounds are also active toward cellular PKCζ without loss of potency compared to the cell-free assay.
Related Papers
- → Allosteric sites: remote control in regulation of protein activity(2015)144 cited
- → ASD v2.0: updated content and novel features focusing on allosteric regulation(2013)102 cited
- → Analysis of tractable allosteric sites in G protein-coupled receptors(2019)45 cited
- → Toward understanding the molecular basis for chemical allosteric modulator design(2012)39 cited
- → Toward an understanding of the sequence and structural basis of allosteric proteins(2013)29 cited